13.5 billion! Johnson & Johnson sells diabetes business LifeScan again
Johnson & Johnson's diabetes business sold finally settled! Recently, Johnson & Johnson announced that it will accept the acquisition offer of private equity firm Platinum equity to sell its diabetes business LifeScan to Platinum equity for about US$2.1 billion (about 13.5 billion yuan). The transaction is expected to be completed by the end of 2018. Diabetes care is one of Johnson & Johnson's traditional medical device businesses, including Animas Corporation and Calibra Medical Inc. And LifeScan's three major sections, where Animas Corporation focuses on insulin pumps, Calibra Medical focuses on diabetes care, products such as wearable insulin patches, and LifeScan focuses on blood glucose monitoring devices such as blood glucose meters and blood glucose test strips. According to LifeScan's official website, the company was founded in 1986 and is headquartered in Pennsylvania, USA. It has manufacturing facilities in Puerto Rico and Scotland. It has more than 3,000 employees worldwide. Its main product is LifeScan OneTouch. In the United States alone, there are more than 5 million people every day. Test your blood sugar with LifeScan OneTouch. However, according to Reuters reports, the above three companies have not brought growth to Johnson & Johnson's diabetes care business, and have been declining since 2012, only in January-September 2017, Johnson & Johnson's diabetes business sales The amount dropped by 7.7% year-on-year. Johnson & Johnson clearly mentioned in the 2016 annual report that the decline in (diabetes care) business was mainly due to falling prices and competitive pressures, and hoped to sell these assets with insufficient profitability, focusing on core business. Improve core competitiveness. In 2017, Johnson & Johnson took the first step in the sale of diabetes business and sold the Animas insulin pump business to Medtronic. At the beginning of this year, Johnson & Johnson announced the evaluation of the strategic options for handling LifeScan and Calibra Medical. At that time, it was reported that China's blood glucose meter manufacturer Sannuo Bio is interested in forming a joint consortium with China Construction Investment to bid for Johnson & Johnson. However, Johnson & Johnson has accepted the offer of Platinum equity, and Sanno has missed LifeScan. It is understood that Platinum Equity is a well-known private equity fund in the United States. Its M&A field is quite diversified. It has also completed the acquisition of Philips Healthcare's Healthcare Products Group (HCP) business in the United States more than a decade ago. Film, radiology reagents and related equipment and accessories. Following the sale of Animas Corporation and LifeScan, Johnson & Johnson's diabetes business will only be left with diabetes care company Calibra Medical Inc. Some insiders have speculated that this section may or may soon be included in the sale schedule. Electric Cable Reel,Electric Hose Reel,Electric Garden Hose Reel,Retractable Electric Cord Reel NINGBO QIKAI ENVIRONMENTAL TECHNOLOGY CO.,LTD , https://www.cxhosereel.com